This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cho, L. Articles by Lincoff, A. M. Search for Related Content PubMed PubMed Citation Articles by Cho, L. Articles by Lincoff, A. M.

CLINICAL STUDIES

Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender

Pooled analysis from EPIC, EPILOG and EPISTENT trials

Leslie Cho, MD^a, Eric J. Topol, MD, FACC^a, Craig Balog, BA^a, Joanne M. Foody, MD^a, Joan E. Booth, RN^a, Catherine Cabot, MD^*, Neal S. Kleiman, MD, FACC, James E. Tcheng, MD, FACC, Robert Califf, MD, FACC and A. Michael Lincoff, MD, FACC^a

^a Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
^* Centocor Incorporated, Cleveland, Ohio, USA
Baylor College of Medicine, Houston, Texas, USA
Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA

Manuscript received August 13, 1999; revised manuscript received February 11, 2000, accepted March 30, 2000.

Reprint requests and correspondence to: Dr. A. Michael Lincoff, Desk F25, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, Ohio 44195
lincofa{at}ccf.org

OBJECTIVES

We sought to determine the efficacy and safety of platelet glycoprotein IIb/IIIa receptor (GP IIb/IIIa) blockade with abciximab in women undergoing percutaneous coronary intervention.

BACKGROUND

Although gender differences in response to platelet glycoprotein IIb/IIIa receptor blockade have been described, there have been no large clinical studies to assess these differences.

METHODS

Outcomes were determined using meta-analysis technique.

RESULTS

In the pooled analysis, the primary end point of death, myocardial infarction (MI) or urgent revascularization within 30 days was reduced from 11.3% to 5.8% (p < 0.001) in men and from 12.7% to 6.5% (p < 0.001) in women treated with abciximab. At six months, death, MI or urgent revascularization was reduced from 14.1% to 8.3% (p < 0.001) in men and 16.0% to 9.9% (p < 0.001) in women receiving abciximab. At one year, mortality was reduced from 2.7% to 1.9% (p = 0.06) in men and 4.0% to 2.5% (p = 0.03) in women treated with abciximab. Major bleeding events occurred in 2.9% versus 3.0% (p = 0.96) of women and 2.7% versus 1.3% (p = 0.003) of men treated with placebo versus abciximab, respectively. Minor bleeding events occurred in 4.7% versus 6.7% (p = 0.01) of women and 2.3% versus 2.2% (p = 0.94) of men treated with placebo versus abciximab, respectively.

CONCLUSIONS

This pooled analysis demonstrated no gender difference in protection from major adverse outcomes with GP IIb/IIIa inhibition with abciximab. Although women had higher rates of both major and minor bleeding events with abciximab compared with men, major bleeding in women was similar with and without abciximab. There was a small increased risk of minor bleeding with abciximab in women.

Abbreviations and Acronyms   ACC/AHA = American College of Cardiology/American Heart Association   ACT = activated clotting time   CABG = coronary artery bypass graft   CHF = congestive heart failure   EPIC = Evaluation of 7E3 for the Prevention of Ischemic Complications trial   EPILOG = Evaluation of Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab Glycoprotein IIb/IIIa Blockade trial   EPISTENT = Evaluation of Platelet IIb/IIIa Inhibitor for Stenting trial   GP IIb/IIIa = Glycoprotein IIb/IIIa receptor   MI = myocardial infarction   PCI = percutaneous coronary intervention   PTT = partial thromboplastin time

This article has been cited by other articles:

				J. S. Berger, D. L. Bhatt, C. P. Cannon, Z. Chen, L. Jiang, J. B. Jones, S. R. Mehta, M. S. Sabatine, S. R. Steinhubl, E. J. Topol, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J. Am. Coll. Cardiol., November 17, 2009; 54(21): 1935 - 1945. [Abstract] [Full Text] [PDF]

				L. J. Shaw, R. Bugiardini, and C. N. B. Merz Women and ischemic heart disease: evolving knowledge. J. Am. Coll. Cardiol., October 20, 2009; 54(17): 1561 - 1575. [Abstract] [Full Text] [PDF]

				A. K. Jacobs Coronary Intervention in 2009: Are Women No Different Than Men? Circ Cardiovasc Interv, February 1, 2009; 2(1): 69 - 78. [Full Text] [PDF]

				H. R. Reynolds, M. E. Farkouh, A. M. Lincoff, A. Hsu, E. Swahn, Z. P. Sadowski, J. A. White, E. J. Topol, J. S. Hochman, and for the GUSTO V Investigators Impact of Female Sex on Death and Bleeding After Fibrinolytic Treatment of Myocardial Infarction in GUSTO V Arch Intern Med, October 22, 2007; 167(19): 2054 - 2060. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]

				L. Pilote, K. Dasgupta, V. Guru, K. H. Humphries, J. McGrath, C. Norris, D. Rabi, J. Tremblay, A. Alamian, T. Barnett, et al. A comprehensive view of sex-specific issues related to cardiovascular disease Can. Med. Assoc. J., March 13, 2007; 176(6): S1 - S44. [Abstract] [Full Text] [PDF]

				G W Mikhail Coronary revascularisation in women Heart, May 1, 2006; 92(suppl_3): iii19 - iii23. [Abstract] [Full Text] [PDF]

				M. Stramba-Badiale, K. M. Fox, S. G. Priori, P. Collins, C. Daly, I. Graham, B. Jonsson, K. Schenck-Gustafsson, and M. Tendera Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology Eur. Heart J., April 2, 2006; 27(8): 994 - 1005. [Abstract] [Full Text] [PDF]

				A. J. Lansky, C. Pietras, R. A. Costa, Y. Tsuchiya, B. R. Brodie, D. A. Cox, E. D. Aymong, T. D. Stuckey, E. Garcia, J. E. Tcheng, et al. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial Circulation, April 5, 2005; 111(13): 1611 - 1618. [Abstract] [Full Text] [PDF]

				A. J. Lansky, J. S. Hochman, P. A. Ward, G. S. Mintz, R. Fabunmi, P. B. Berger, G. New, C. L. Grines, C. G. Pietras, M. J. Kern, et al. Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare Professionals From the American Heart Association Circulation, February 22, 2005; 111(7): 940 - 953. [Abstract] [Full Text] [PDF]

				S. D Brouse and V. G Wiesehan Evaluation of Bleeding Complications Associated with Glycoprotein IIb/IIIa Inhibitors Ann. Pharmacother., November 1, 2004; 38(11): 1783 - 1788. [Abstract] [Full Text] [PDF]

				N Danchin Acute coronary syndromes: should women receive less antithrombotic medication than men? Heart, April 1, 2004; 90(4): 363 - 366. [Abstract] [Full Text] [PDF]

				A. K. Jacobs Coronary Revascularization in Women in 2003: Sex Revisited Circulation, January 28, 2003; 107(3): 375 - 377. [Full Text] [PDF]

				J. S. Hochman and J. E. Tamis-Holland Acute Coronary Syndromes: Does Sex Matter? JAMA, December 25, 2002; 288(24): 3161 - 3164. [Full Text] [PDF]

				D. J. Malenka, D. E. Wennberg, H. A. Quinton, D. J. O'Rourke, P. D. McGrath, S. J. Shubrooks Jr, G. T. O'Connor, T. J. Ryan Jr, J. F. Robb, M. A. Kellett Jr, et al. Gender-related changes in the practice and outcomes of percutaneous coronary interventions in northern New England from 1994 to 1999 J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2092 - 2101. [Abstract] [Full Text] [PDF]

				L. S. Fernandes, J. E. Tcheng, J. C. O'Shea, B. Weiner, T. J. Lorenz, C. Pacchiana, L. G. Berdan, K. J. Maresh, D. Joseph, M. Madan, et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?: Lessons from the ESPRIT study J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1085 - 1091. [Abstract] [Full Text] [PDF]

				W Maier, S Windecker, E Boersma, and B Meier Evolution of percutaneous transluminal coronary angioplasty in Europe from 1992-1996 Eur. Heart J., September 2, 2001; 22(18): 1733 - 1740. [Abstract] [PDF]